Elevated PIVKA-II is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 16, 2014, Pages 6673-6678

  Wang, Bei Li ^a   Tan, Qi Wen ^a   Gao, Xing Hui ^a   Wu, Jiong ^a   Guo, Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

BCLC; Hepatocellular carcinoma; PIVKA II; Prognosis; Recurrence

Indexed keywords

BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

BLOOD; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER NEOPLASMS; LIVER RESECTION; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84906837694     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.16.6673     Document Type: Article

References (25)

1. Bertino G, Ardiri A, Malaguarnera M, et al (2012). Hepatocellualar carcinoma serum markers. Semin Oncol, 39, 410-33.
2. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.
3. Cai XY, Wang JX, Yi Y, et al (2014). Low counts of γδ T cells in peritumoral liver tissue are related to more frequent recurrence in patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev, 15, 775-80.
4. Cha C, Fong Y, Jarnagin WR, et al (2003). Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg, 197, 753-8.
5. Chan SL, Mo FK, Johnson PJ, et al (2009). New utility of an old marker: serial-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol, 27, 446-52.
6. Gupta SP, Mittal A, Sathian B, et al (2013). Elevated serum insulin is an independent risk factor for hepatocellular carcinoma: a case control study from Nepal. Asian Pac J Cancer Prev, 14, 7331-3.
7. Kang SH, Kim do Y, Jeon SM, et al (2012). Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol, 24, 849-56.
8. Kim do Y, Paik YH, Ahn SH, et al (2007). PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology, 72, 52-7.
9. Kim JM, Hyuck C, Kwon D, et al (2013). Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma. World J Surg, 37, 1371-8.
10. Li N, Hu WJ, Shi J, et al (2013). Roles of fibroblast growth factor-inducible 14 in hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 3509-14.
11. Lovet JM, Brú C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38.
12. Matsubara M, Shiraha H, Kataoka J, et al (2012). Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol, 27, 1602-8.
13. Mittal A, Gupta SP, Sathian B, et al (2012). Des-gamma-carboxyprothrombin for early identification and prognosis of hepatocellular carcinoma: a case control study from western Nepal. Asian Pac J Cancer Prev, 13, 5773-5.
14. Park H, Park JY (2013). Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int, 310427.
15. Santi V, Trevisani F, Gramenzi A, et al (2010). Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol, 53, 291-7.
16. Shah SA, Greig PD, Gallinger S, et al (2006). Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg, 202, 275-83.
17. Shah SA, Cleary SP, Wei AC, et al (2007). Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery, 141, 330-9.
18. Shi L, Wu LL, Yang JR, et al (2014). Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients. Asian Pac J Cancer Prev, 15, 2979-86.
19. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
20. Takayama T, Makuuchi M, Kojiro M, et al (2008). Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol, 15, 972-8.
21. Tung-Ping Poon R, Fan ST, Wong J (2000). Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg, 232, 10-24.
22. Wang SB, Cheng YN, Cui SX, et al (2009a). Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis, 26, 469-77.
23. Wang CC, Iyer SG, Low JK, et al (2009b). Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol, 16, 1832-42.
24. Wang NY, Wang C, Li W, et al (2014). Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev, 15, 1539-44.
25. Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82.